Skip to content

Does Co-registration of OCT and Angiography Reduce Geographic Miss of Stent Implantation?

Evaluation of Effect of Co-registration Between Optical Coherence Tomography (OCT) and Coronary Angiography Onto OCT Guided Percutaneous Coronary Intervention (PCI)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02671123
Enrollment
200
Registered
2016-02-02
Start date
2016-02-29
Completion date
2016-12-31
Last updated
2016-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

The purpose of this study is to determine whether co-registration of OCT and angiography reduce geographic miss defined as stent edge dissection or significant residual stenosis at stent edge after stent implantation during percutaneous coronary intervention.

Detailed description

Background: When a stent fails to fully cover the lesion, it is termed geographic miss (GM). Optical coherence tomography (OCT) is an intracoronary imaging modality that has higher resolution than conventional intracoronary ultrasound. Although OCT allows identification of the location of the culprit lesion and side branch using automated measures, it is sometimes difficult to identify the exact segment corresponding to angiography. Recently, co-registration of OCT and angiography has become available; however, whether this reduces the incidence of GM during stenting is unknown. Hypothesis: OCT reduces GM during percutaneous coronary intervention. Objectives: 1. Determine the incidence of GM defined as residual disease\* and significant edge dissection† at proximal and distal reference 2. Determine the incidence of stent dislocation (distance between planned and actual stented place) 3. Determine procedural findings (additional stent, total fluoro time, total contrast volume) * Minimum lumen area \<4.0 mm2 in the presence of significant residual plaque within 5 mm distal and proximal to the stent edge. * A flap of vessel wall of \>60° is seen in ≥2 consecutive cross-section image within 5 mm distal and proximal from stent edge Study Design and Methods: Single-center, prospective, randomized study. Consented subjects who are to undergo percutaneous coronary intervention are divided into 2 groups randomly (OCT with co-registration vs OCT without co-registration). After stent deployment guided by OCT, dissection, residual disease at the stent edge, and distance between planned and actual stent location are assessed using OCT or angiography. Additional stent deployment, procedure time, total fluoroscopy time, and total contrast volume are also evaluated. Sample size considerations: OCT with co-registration: 100, OCT without co-registration: 100 (α=0.05, β =0.2). In a retrospective evaluation, the incidence of residual disease (lumen area \<4.0 mm2 in the presence of significant residual plaque) or significant stent edge dissection was 36% (18/50, 34% \[17/50\] with residual stenosis, 4% \[2/50\] with significant edge dissection). Under the assumption that GM occurs in 36% of patients without co-registration and 18% of patients with co-registration, a group of 190 patients yields a power 80% (with a 2-sided α=0.05) to detect a difference in GM between patients with and without co-registration. In order to account for patient drop out and non-evaluable OCT recordings (5%), a total of 200 patients will be enrolled.

Interventions

PROCEDURECoronary PCI with OCT with Co Registration

Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.

PROCEDURECoronary PCI with OCT without Co Registration

Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.

Sponsors

CardioVascular Research Foundation, Korea
CollaboratorOTHER
St. Francis Hospital, New York
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Patients ≥18 years old who undergo percutaneous coronary intervention per clinical indications.

Exclusion criteria

* Left main disease * Ostial lesion at Right Coronary Artery * Tortuous artery in which OCT is unable to pass * Lesion at bypass graft * In-stent restenosis * Chronic total occlusion * Cardiogenic shock (sustained \[\>10 min\] systolic blood pressure \<90 mm Hg in absence of inotropic support or the presence of an intra-aortic balloon pump) * Acute phase heart failure * Sustained ventricular arrhythmias * Known ejection fraction \<35% * Known severe valvular heart disease Known severe renal insufficiency (estimated glomerular filtration rate \<30 mL/min/1.72 m2)

Design outcomes

Primary

MeasureTime frameDescription
Geographic missIntraoperativeGeographic miss defined as evidence of residual disease at stent edge or significant edge dissection after stent deployment

Secondary

MeasureTime frameDescription
Number of participants with stent edge dissectionperi procedureStent edge dissection will be defied as a flap of vessel wall and further categorized as intimal dissection, medial dissection, intramural hematoma, or extra-medial dissection. Minimum lumen area, angle of dissection flap, and length of dissection will be measured by OCT by a core lab who is blinded to the randomization.
Distance between the planned and actual stent locationIntraoperativeDistance between the planned and actual stent location will be defined as the distance between the center of planned stent location and the center of actual stent location which will be recorded on the OCT software and analyzed by a core lab who is blinded to the randomization.
Number of additional stents requiredIntraoperativeThis will be measured as number of participants with additional stent required.
Number of participants with Residual disease at stented edgeIntraoperativeResidual disease at stent edge will defined as minimum lumen area within 5mm from the stent edge evaluated by OCT. This measurement will be analyzed by a core lab independently who will be blinded for randomization.
Total fluoroscopy timeintraoperativetotal amount of fluoroscopy time used during procedure
Total contrast volumeintraoperativetotal mount of contrast in ml used during entire PCI procedure
Procedure timeIntraoperativetime of PCI procedure defined as time vascular access obtained until guide catheter removed from access site.

Countries

United States

Contacts

Primary ContactRichard A Shlofmitz, MD
richard.shlofmitz@chsli.org516-390-9640
Backup ContactElizabeth S Haag, RN MPA
elizabeth.haag@chsli.org516 562-6790

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026